Finding New Opportunities In Obesity With Moonwalk Bioscience's Alex Aravanis, M.D., Ph.D.

Moonwalk is betting genetics-derived, non-appetite-suppressing siRNA targets can address the roughly 25-33% of patients GLP-1s don't fully help.

• $70M Series B closed: Oversubscribed round funds lead candidate W101 into Phase 1 by end of 2027, plus a second near-development-candidate program and possibly a third.
• Adipose-targeted siRNA licensed from China: Moonwalk licensed adipose-targeting chemistry from Sirius (Suzhou) Biotechnology, adding it to sequences against novel genetic targets discovered via Feng Zhang's genome-perturbation platform.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.